

DS  
a monoclonal human [sequence] immunoglobulin comprising a VkL19 segment, a Jk2 segment, and a light chain CDR3 region comprising the sequence QQANSFPYT (SEQ ID NO:69), and

a monoclonal human [sequence] immunoglobulin comprising a VkL15 segment, a Jk2 segment, and a light chain CDR3 region comprising the sequence QQYDSYPYT (SEQ ID NO:70).

REMARKS

STATUS

Claims 13, 14, 22-29, 37, 40, 50-51 and 53 are pending following entry of this amendment.


Support for the amendments to claims 13, 22-29, 37, 40, 50-51 and 53 is found throughout the specification and in the claims originally filed. Claim amendments are for purposes of improved clarity or consistency of claim language unless otherwise noted. No claim amendment should be construed as an acquiescence in any ground of rejection.

The claims were amended as suggested by the examiner in the Office Action mailed February 17, 2000 and to expedite prosecution. Specifically, the examiner invited Applicants to claim CD4-specific human monoclonal antibodies with all of the appropriate sequences that provide for binding CD4.

CONCLUSION

Applicants intend to file a second Preliminary Amendment in this CPA to further address the issues raised in the Office Action dated February 17, 2000 after the Examiner responds to Applicants' response and amendment filed July 17, 2000. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

  
Andrew T. Serafini  
Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Telephone: (650) 326-2400  
Facsimile: (650) 326-2422  
ATS  
PA 3083424 v1